Rafael Holdings, Inc. (RFL) Stock

Real Estate · Real Estate Services · Member of Other US Stocks

Rafael Holdings, Inc. (RFL) closed at USD 1.43 on 2026-10-14, a change of +6.7 % over the past year, with a market capitalization of USD 76.44M.

Rafael Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Rafael Holdings, Inc. key figures

Previous close

USD 1.43 (2026-10-14)

1-year change

+6.7 %

Market cap

USD 76.44M

Enterprise value

USD 51.97M

P/E ratio (trailing)

-2.07

P/E ratio (forward)

n/a

EPS (trailing)

-0.71

EPS (forward)

n/a

PEG ratio

n/a

Price to book

1.01

Revenue growth

-50.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.44

Employees

21

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Rafael Holdings, Inc. and compare it with other stocks.